The belief among genomics experts that one day drugs would be given based on genomic abnormalities that cut across tumor types became reality this week.
The coverage decision limits the test to patients with advanced lung cancers who haven't been genomically profiled and who can't receive tissue-based testing.
The money will fund a new plan to sequence tumor DNA from more than 1 million cancer patients. The firm also announced a new JV in Asia, the Middle East, and Africa.
